Procter & Gamble has just cleared its fiscal Q4 2026 print, and the question is no longer what the numbers say but whether the market decides the stock deserves to close its underperformance gap against a peer group that ran sharply harder into the release.
The peer divergence is the standout context for this week. P&G gained half a percent on the week to close at $148.88. Colgate-Palmolive added 2.5%, Church & Dwight rose 4.4%, Kimberly-Clark gained 4.7%, and Clorox jumped nearly 5%. P&G lagged every major name in its peer group by a meaningful margin. That gap accumulated while short sellers were quietly trimming — short interest fell 16% over the past month to just under 1% of free float, and dropped another 6% in the single session on July 28. The direction of short-side positioning has moved from cautious rebuilding into the print to active reduction after it, which shifts the near-term technical backdrop modestly.
The lending market has nothing interesting to add. Borrow availability is at the maximum reading — over 1.4 billion shares remain available, a figure so large relative to the float it represents no constraint on new short positions whatsoever. Cost to borrow is 0.33%, up roughly 26% on the week in percentage terms but still deeply nominal in absolute terms. There is no squeeze pressure, no borrow-driven tension, and no signal from the lending side of the market worth anchoring to.
Options positioning entered the print slightly call-leaning but well within normal range. The put/call ratio came in at 0.65, about 0.7 standard deviations below its 20-day mean of 0.68. That is a mild tilt toward calls — not conviction, but also not the defensive hedging that characterised mid-June, when the PCR peaked at 1.11. The options market was pricing neither a blowout nor a breakdown; it was essentially agnostic. Whether that agnosticism proves correct depends on how the market reads whatever Q4 numbers landed this morning.
The Street's positioning around the print has been a gentle downward drift in targets from the major firms. JP Morgan trimmed to $162 from $164 earlier in July while holding Overweight. Bank of America cut to $166 from $170 earlier in the month, also holding Buy. Barclays went the other way, raising its target to $152 from $146 on July 21, though it kept an Equal-Weight rating — a signal that even the upgrade reflects more relief than genuine enthusiasm. The mean target across the analyst community is $163.56, implying roughly 10% upside from the $148.88 close. Against that, the P/E ratio has compressed about 0.75 turns over the past 30 days, and EV/EBITDA has shed half a turn. Valuation is drifting modestly cheaper rather than expanding, which is consistent with a market that was waiting on the print before committing.
Factor scores provide the cleanest read on where the stock sits structurally. The dividend score ranks in the 98th percentile — PG remains a core income holding. Analyst recommendation dispersion ranks in the 95th percentile, meaning the sell-side is unusually aligned on direction. EPS momentum over the past 30 days scores in the 85th percentile, suggesting estimates were moving higher into the number. Against those positives, the 12-month forward EPS growth score sits in the 34th percentile — the market is not paying for an acceleration story. The ORTEX short score at 29.97 is low and has barely moved all week, consistent with a stock where short-side pressure is structurally absent rather than actively building or unwinding.
How the stock responds to whatever it reported this morning — and whether it can close any of the gap opened up by KMB, CHD, and CLX — is now the only number worth watching.
See the live data behind this article on ORTEX.
Open PG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
